The growth of Viagra and its impact on the drug landscape presents a complex question for shareholders. While the first sales figures were remarkable, the exclusivity has ended, leading to a wave of off-brand https://jeancire879654.blog-a-story.com/23211495/the-blue-pill-and-pharma-a-risky-opportunity